@article{c15ab64693204056a674fac5b4d815c0,
title = "Prenatal antidepressant exposure and the risk of attention-deficit hyperactivity disorder in children: A systematic review and meta-analysis",
abstract = "This systematic review assesses the association between prenatal antidepressant exposure and risk of ADHD in children. Electronic databases were searched up to 25 July 2017. Observational studies examining this association were included in the review and meta-analysis was conducted where appropriate. Eight relevant studies were identified. The seven studies included in the meta-analysis comprised a total of 2,886,502 children. The pooled estimates comparing prenatal exposure to non-exposure showed an adjusted rate ratio (aRR) of 1.39 (95%CI 1.21-1.61). Similarly, an increased risk was found comparing previous antidepressant users and non-users: aRR = 1.56 (95%CI 1.25-1.95). The relationship between maternal psychiatric conditions and ADHD in children yielded an aRR of 1.90 (95%CI 1.47-2.45). Three studies conducted sibling-matched analyses with aRR of 0.94 (95%CI 0.75-1.16). These data suggest that the observed association between prenatal use of antidepressants and risk of ADHD in offspring can be partially explained by confounding by indication because the results from sibling-matched analyses do not support an increased risk of ADHD in discordant exposed siblings.",
keywords = "Antidepressant, Attention-deficit/hyperactivity disorder, Pregnancy",
author = "Man, {Kenneth K. C.} and Chan, {Esther W.} and Patrick Ip and David Coghill and Emily Simonoff and Chan, {Phyllis K. L.} and Lau, {Wallis C. Y.} and Schuemie, {Martijn J.} and Sturkenboom, {Miriam C. J. M.} and Wong, {Ian C. K.}",
note = "Dr. Esther Chan reports grants from Janssen (a division of Johnson & Johnson), BMS, Pfizer, The Research Grants Council (RGC, Hong Kong), received for other work. Prof. Coghill reports grants from The European Union FP7 Programme and Shire, and honoraria from Shire, Eli Lilly, Novartis and Janssen-Cilag, acted as an advisor to Shire and Lundbeck and received royalties from Oxford University Press. Prof. Coghill was a member of British Association for Psychopharmacology ADHD, Depression and Bipolar disorder guideline groups. Prof. Simonoff reports grants from Innovative Medicines Initiative (IMI), National Institute for Health Research Program Grant for Applied Research and the NIHR Biomedical Research Centre for Mental Health. Dr Ip reports grants from the Research Grants Council (RGC, Hong Kong) and the Health and Medical Research Fund (Food and Health Bureau, Hong Kong). Prof. Wong reports grants from The Research Grants Council (RGC, Hong Kong), Innovative Medicines Initiative (IMI), Shire, Janssen-Cilag, Eli-Lily, Pfizer, European Union FP7 Programme, outside the submitted work. Prof. Wong is a member of the National Institute for Health and Clinical Excellence (NICE) ADHD Guideline Group and was a member of the British Association for Psychopharmacology ADHD Guideline Group and acted as an advisor to Shire. Dr Phyllis Chan acted as an advisor to Eli Lilly. Prof Sturkenboom is leading a research group that received grants for specific post-authorisation safety projects from Novartis, Boehringer, GSK and Servier, none related to this topic. Dr Schuemie is a full-time employee and shareholder of Johnson & Johnson. Other authors report no competing interests; no other relationships or activities have been declared that could appear to have influenced the submitted work.",
year = "2018",
month = mar,
doi = "10.1016/j.neubiorev.2017.12.007",
language = "English",
volume = "86",
pages = "1--11",
journal = "Neuroscience and Biobehavioral Reviews",
issn = "0149-7634",
publisher = "Elsevier",
}